CP
GSK icon

Camelot Portfolios’s GSK GSK Stock Holding History

Camelot Portfolios’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-14,981
Closed -$716K – 247
2018
Q4 		$716K Buy
14,981
+189
+1% +$9.31K 0.33% 91
2018
Q3 		$743K Sell
14,792
-233
-2% -$11.8K 0.33% 83
2018
Q2 		$757K Buy
15,025
+8,551
+132% +$431K 0.32% 86
2018
Q1 		$801K Sell
6,474
-10,159
-61% -$473K 0.37% 76
2017
Q4 		$737K Sell
16,633
-232
-1% -$10.7K 0.35% 78
2017
Q3 		$856K Buy
16,865
+454
+3% +$23K 0.41% 69
2017
Q2 		$885K Sell
16,411
-218
-1% -$11.6K 0.44% 59
2017
Q1 		$876K Buy
16,629
+96
+0.6% +$4.87K 0.43% 65
2016
Q4 		$796K Sell
16,533
-7,426
-31% -$367K 0.42% 64
2016
Q3 		$1.29M Buy
23,959
+23
+0.1% +$1.26K 0.69% 42
2016
Q2 		$1.3M Sell
23,936
-105
-0.4% -$5.53K 0.76% 38
2016
Q1 		$1.22M Buy
24,041
+858
+4% +$42.7K 0.75% 40
2015
Q4 		$1.17M Buy
23,183
+4,501
+24% +$229K 0.74% 39
2015
Q3 		$898K Buy
18,682
+2,373
+15% +$124K 0.6% 46
2015
Q2 		$849K Buy
16,309
+1,035
+7% +$58.3K 0.49% 58
2015
Q1 		$881K Buy
+15,274
New +$876K 0.51% 52

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Camelot Portfolios's GSK Position: Q1 2019 in Review

Camelot Portfolios sold out of GSK (GSK) in Q1 2019, closing a stake of 14,981 shares — an estimated $716K sold.

Camelot Portfolios first reported a position in GSK in Q1 2015 and held it in 16 quarters. The position peaked at $1.3M in Q2 2016. 847 funds tracked by Wall St. Rank hold GSK as of Q1 2019.

  • Camelot Portfolios reported no remaining GSK position as of Q1 2019 after selling out during the quarter.
  • Camelot Portfolios sold 14,981 GSK shares in Q1 2019, an estimated $716K.
  • Camelot Portfolios first reported a position in GSK in Q1 2015 and held it in 16 quarters.
  • Camelot Portfolios's GSK position peaked at $1.3M in Q2 2016.
  • 847 funds tracked by Wall St. Rank held GSK as of Q1 2019.

Based on Camelot Portfolios's 13F filing for Q1 2019, filed 25 Apr 2019.